podcasts Ratings /ratings/en/research-insights/podcasts/s-p-healthcare-credit-beat-episode-3-four-takeaways-davita content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

In This List

S&P Healthcare Credit Beat - Episode 3: Four Takeaways - DaVita

COMMENTS

COVID-19 Impact: Key Takeaways From Our Articles

COMMENTS

ESG Concerns In Oil And Gas Sectors Led To A Surge In Downgrade Pressure In January, Which Was Realized By Mid-February

COMMENTS

As European Hotels Grapple With Prolonged Restrictions, Are Operators And Landlords Sharing The Pain?

COMMENTS

Pharma Outlook: Eighth Straight Year Of Credit Deterioration In 2021

Listen: S&P Healthcare Credit Beat - Episode 3: Four Takeaways - DaVita

Top two U.S. dialysis player, DaVita, has seen its fair share of headlines over the past year – an upcoming California ballot on dialysis reimbursement, charitable premium assistance controversy, and a pending sale of DMG. What does all this mean for DaVita’s ratings? Healthcare analysts, Ji Liu and Arthur Wong, discuss on the Beat what they are focusing on for the ratings on DaVita.

Register with S&P Global Ratings

Register now to access exclusive content, events, tools, and more.

Go Back